Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research

Abstract

Lactacystin exemplifies the role that serendipity plays in drug discovery and why "finding things without actually looking for them" retains such a pivotal role in the search for the useful properties of chemicals. The first proteasome inhibitor discovered, lactacystin stimulated new possibilities in cancer control. New and innovative uses are regularly being found for lactacystin, including as a model to study dementia, while new formulations and delivery systems may facilitate its use clinically as an anticancer agent. All this provides yet more evidence that we need a comprehensive, collaborative and coordinated programme to fully investigate all new and existing chemical compounds, especially those of microbial origin. We need to do so in order to avoid failing to detect and successfully exploit unsought yet potentially life-saving or extremely advantageous properties of microbial metabolites.

Fig. 1

Structure of lactacystin and producing organism

Fig. 2

Immunofluorescence staining of 200 kDa neurofilaments in Neuro 2a cells

Fig. 3

Structures of proteasome inhibitors